DASPERSE = Dasatinib in chronic phase myeloid leukemia patients with chronic toxicity to imatinib

Study title

Dasatinib in chronic phase myeloid leukemia patients with chronic toxicity to imatinib [Asia, Europe, USA]

Scientific title

A Phase IV, Open-label, Multicenter Study of Dasatinib in Chronic-Phase Chronic Myeloid Leukemia (CP-CML) Patients With Chronic, Low-grade Non-Hematologic Toxicity to Imatinib (EudraCT 2011-006180-21, ClinicalTrials.gov NCT01660906)

Indication and most important inclusion criteria

Potential study participants must be 18 years or older with CP CML achieving an optimal response (either complete hematologic response (CHR) by 3 months, partial cytogenetic response (PCyR) by 6 months, or complete cytogenetic response (CCyR) by 12 months) to imatinib treatment. They are currently experiencing at least one imatinib-related Grade 1 or 2 non-hematologic adverse events persisting for at least 2 months or recurring at least 3 times in the preceding 12 months, despite best supportive care.
To be enrolled in this study, patients must have a daily ECOG performance status not higher than 2 and a life expectancy of more 6 than months. Kidney and liver function should be adequate.

Short description of intervention

This study will assess the frequency of reduction or resolution of imatinib-related chronic Grade 1 or Grade 2 non-hematologic adverse events at 3 months after switch to dasatinib.

Type of study

Second line trial

Current status

Active, but no longer recruiting

Study sponsor

Bristol-Myers Squibb

Scientific lead / contact

Bristol-Myers Squibb

Principal investigator

...

Additional information

Study description in the EU Clinical Trials Register which is hosted by the European Medicines Agency (EMA)

Study description in the US register ClinicalTrials.gov, a service of the U.S. National Institutes of Health

Brief protocol in Kompetenznetz Leukämie 

 

Study centers / principal investigators

France

Creteil Cedex, 94010

Lille Cedex, 59037

Pierre Benite cedex, 69495

Pringy Cedex, 74374

Vandoeuvre les Nancy, 54511

 

Germany

Jena
Universitätsklinikum Jena
Klinik und Poliklinik für Innere Medizin II
Prof. Dr. med. Andreas Hochhaus

Köln, 50937

Lübeck, 23562

Mannheim, 68169

Rostock, 18055

 

Italy

Catania, 95124

Firenze, 50134

Roma, 00144

Roma, 00161

Torino, 10126

 

Korea, Republic of


Seoul, 137-701

 

United States

Pacific Cancer Medical Center
Anaheim, California, 92801
Ajit Maniam

Cancer Center of Central Connecticut
Southington, Connecticut, 06489

St. Agnes Healthcare, Inc
Baltimore, Maryland, 21229
Peter Byeff

Promedica Hematology & Oncology Assoicates
Sylvania, Ohio, 43560
William R. Horvath

The University of Texas MD Anderson Cancer Center
Houston, Texas, 77030
Jorge E. Cortes

 

 

DASFREE (CA180-406) = Discontinuation of dasatinib in CP-CML patients with stable MR4.5

Study title

DASFREE (CA180-406) = Open study to assess discontinuation of dasatinib treatment in CP-CML patients with stable MR4.5 [Europe, North America]

Scientific title

Open-Label Single Arm Phase 2 Study Evaluating Dasatinib Therapy Discontinuation in Patients With Chronic Phase Chronic Myeloid Leukemia (CP-CML) With Stable Complete Molecular Response (CMR) DASFREE
(EudraCT No. 2012-001421-27 / Clinicaltrials.gov No. NCT01850004)

Indication and most important inclusion criteria

Men and women diagnosed with CML in chronic phase, who have been treated with Dasatinib for at least 2 years at the time of enrollment and who are in Dasatinib-induced complete molecular remission for at least 1 year before study entry

Patients are eligible for the screening assessment from the central lab if they have been in stable dasatinib induced CMR for at least one year, documented by at least three assessments, conducted 2.5 - 6.5 months apart, at a local lab. The first screening assessment conducted at the central lab will be repeated after three months, if the first assessment confirms CMR (MR 4.5). Patients are eligible for enrollment if both assessments from the central lab confirm ≤ 0.0032% International Scale (IS) or MR4.5.

Patients with CML in chronic phase treated with Dasatinib as first line treatment or patients with CML in chronic phase receiving Dasatinib in second line after treatment with a tyrosine-kinase inhibitor (TKI)

Patients with a life expectancy of more than 1 year.

Short description of intervention

The study tests whether patients with CML in chronic phase and with stable CMR who discontinue Dasatinib treatment are able to maintain a sustained remission in the long-term (= 12 months after Dasatinib discontinuation without restarting Dasatinib), with undetectable or minimally detectable BCR-ABL residual disease.

Type of study

Treatment discontinuation trials

Current status

No longer recruiting

Study sponsor

Bristol-Myers Squibb

Scientific lead / contact

Bristol-Myers Squibb

Principal investigator

See site contact information

Additional information

Study description in US register ClinicalTrials.gov, a service of the U.S. National Institutes of Health

For more information regarding BMS clinical trial participation, please visit www.BMSStudyConnect.com

Study centers / principal investigators

Canada

Local Insitution
Toronto, Ontario, Canada, M5G 2M9

France

Local Institution
Paris Cedex 10, 75475

Local Institution
Pessac, 33604

Local Institution
Pierre Benite, 69310

Local Institution
Vandoeuvre les Nancy, 54511

Germany

Aachen
Universitätsklinikum Aachen

Berlin
Local Institution
13353 Berlin

Mannheim
Medizinische Fakultät Mannheim der
der Ruprecht-Karls-Universität Heidelberg
III. Medizinische Klinik

Rostock
Local Institution
18055 Rostock

Ulm
Local Institution
89081 Ulm


Italy

Local Institution
Catania, 95124

Local Institution
Firenze, 50134

Local Institution
Napoli, 80131

Local Institution
Orbassano, 10043

Local Institution
Roma, 00144

Local Institution
Roma, 00161

 

Spain

Local Institution
Las Palmas de Gran Canaria, Spain, 35010

Local Institution
Madrid, 28034

Local Institution
Malaga, 29010

Local Institution
Oviedo, 33011


United States

California
City of Hope Medical Center
Duarte, California, 91010

David Geffen School of Medicine at Ucla
Los Angeles, 90095

Ucsf Division Of Hematology And Oncology
San Francisco, California, 94143

New Jersey
John Theurer Cancer Center At Hackensack University Medical Center
Hackensack, New Jersey, 07601

New York
Columbia University Medical Center (Cumc)
New York, New York, 10032

Texas
Baylor Charles A. Sammons Cancer Center
Dallas, Texas, 75246


 

 

 

BYOND (B1871039) = Safety and Efficacy of Bosutinib in Ph+ CML Previously Treated with TKI

Study title

Bosutinib In Patients With Philadelphia Chromosome Positive Chronic Myeloid Leukemia Previously Treated With One Or More Tyrosine Kinase Inhibitors [Europe, USA]

Scientific title

A Phase 4 Safety And Efficacy Study Of Bosutinib In Patients With Philadelphia Chromosome Positive Chronic Myeloid Leukemia Previously Treated With One Or More Tyrosine Kinase Inhibitors (EudraCT Number 2013-003250-25; Clinicaltrials.gov No. NCT02228382)

Indication and most important inclusion criteria

To be considered for inclusion in this study patients must have confirmed Philadelphia Chromosome positive Chronic Myelogenous Leukemia (Ph+ CML) or confirmed BCR-ABL1 if Philadelphia Chromosome negative Chronic Myelogenous Leukemia (Ph- CML) from initial diagnosis.

They have previously been treated with one or more tyrosine kinase inhibitor (TKI) drugs (imatinib, dasatinib and/or nilotinib) for Philadelphia Chromosome positive CML. CML may be in any phase, as long as the patient is unable to receive treatment with imatinib, dasatinib and/or nilotinib for any reason.

Patients must be 18 years or older and have adequate bone marrow, liver and kidney functions.
They should have an ECOG of 0-1 if in Chronic Phase or of 0-3 if they are treated fourth line (and beyond) in Chronic Phase or if they are in Accelerated Phase or Blast Phase.

Short description of intervention

This study evaluates the safety and efficacy of bosutinib in patients with Ph+ CML previously treated with one or more tyrosine kinase inhibitors. It includes 150 Philadelphia Chromosome Positive Chronic Myeloid Leukemia patients with high unmet medical need, including 75 Chronic Phase, Accelerated Phase or Blast Phase patients in the fourth or later line treatment setting (after treatment with at least three other tyrosine kinase inhibitors).

Bosutinib will be administered at 500 mg once a day for up to 4 years.

Type of study

Other trials
In multiple countries

Current status

Study enrollment is closed

Study sponsor

Pfizer

Scientific lead / contact

Jocelyn Leone

Principal investigator

Prof. Andreas Hochhaus
Universitätsklinikum Jena, Germany

Additional information

Study description in the US register ClinicalTrials.gov, a service of the U. S. National Institutes of Health

Study description in the EU Clinical Trials Register which is hosted by the European Medicines Agency (EMA)

Study centers / principal investigators

Austria

Innsbruck
Universitaet Innsbruck

Linz
Hospital "Barmherzige Schwestern"
Internal Medicine I

Belgium

Antwerpen
Ziekenhuis Netwerk Antwerpen


France

Bordeaux
Institut Bergonie
Bordeaux Cedex 09

Le Chesnay Cedex
Centre Hospitalier de Versailles Hopital Andre Mignot

Marseille
Centre Regional De Lutte Contre Le Cancer

Nice
Nice Hopital Archet 1
Service Hematologie clinic
Nice Cedex 3

Toulouse cedex 9
IUCT - ONCOPOLE
Toulouse cedex 9

Vandoeuvre-les-Nancy
CHU Brabois


Germany

Aachen
Uniklinik RWTH Aachen

Berlin
Charité Universitaetsmedizin Berlin

Cologne
Universitätsklinikum Köln

Hamburg
Universitaetsklinikum Hamburg-Eppendorf

Jena
Universitätsklinikum Jena

Mannheim
CML Studienzentrale
III. Medizinische Klinik, Universitätsmedizin Mannheim


Italy

Bari
U.O. Ematologia con Trapianto – A.O.U. Policlinico Consorziale

Bologna
A.O.U. Policlinico S. Orsola-Malpighi, U.O. Ematologia

Catania
AOU Policlinico Vittorio Emanuele - P.O. Ferrarotto - UOC Ematologia
Divisione Clinicizzata di Ematologia

Firenze
SOD Ematologia

Milano
Ospedale Niguarda Ca Granda - SC Ematologia

Monza
A.O. San Gerardo - U.O. Ematologia Adulti
Unita Operativa Ematologia Adulti

Napoli
AOU Federico II

Orbassano
AOU San Luigi Gonzaga

Rome
Ospendale S. Eugenio – UOC Ematologia

Udine
Azienda Ospedaliero-Universitaria Santa Maria della Misericordia die Udine

 

Norway

Bergen
Haukeland universitetssjukehus

Trondheim
St Olavs Hospital


Spain

Barcelona
Hospital Clinic I Provincial de Barcelona

Barcelona
Hospital Universitari Vall d'Hebron

Madrid
Hospital Ramon y Cajal

Madrid
Hospital Universitario de La Princesa

Pamplona
Complejo Hospitalario de Navarra Hematologia

Pozuelo De Alacron
Hospital Universitario Quiron Madrid

Salamanca
Clinico Universitario de Salamanca

Valencia
Hospital Universitari i Politecnic La Fe

Zaragoza
Hospital de Dia Quiron Zaragoza

 

Sweden

Stockholm
Hematologiskt Centrum

Uppsala
Akademiska sjukhuset


USA

California
University of Southern California/Norris Comprehensive Cancer Center, Los Angeles

Keck Hospital of USC, Los Angeles

LAC&USC Medical Center, Los Angeles


Florida
University of Miami Hospital & Clinics, Miami


Indiana
Indiana Blood and Marrow Transplantation-Clinic
Indianapolis


Maryland
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore


Missouri
Washington University School of Medicine, St. Louis

Siteman Cancer Center-West County, Creve Coeur

Siteman Cancer Center-South County, St. Louis

Barnes-Jewish Hospital, St. Louis


New York
Weill Cornell Medical College – Presbyterian Hospital

Washington
Seattle Cancer Care Alliance
Seattle

LAST Stopping Tyrosine kinase inhibitors

Study title

The LAST Study - The Life After Stopping Tyrosine Kinase Inhibitors Study [USA]

Scientific title

The Life After Stopping Tyrosine Kinase Inhibitors Study (ClinicalTrials.gov No. NCT02269267)

Indication and most important inclusion criteria

This study includes patients 18 years and older diagnosed with chronic myeloid leukemia (CML) in chronic phase. To be eligible for inclusion, patients will currently be taking imatinib, dasatinib, nilotinib or bosutinib. They will have been taking tyrosine kinase inhibitors for at least 3 years.

Patients are eligible if they have documented undetectable BCR-ABL by PCR for at least 2 years before screening, according to their local lab. Patients who enroll will have two screening PCRs by central lab before stopping their tyrosine kinase inhibitor.

Short description of intervention

they are considering stopping their tyrosine kinase inhibitor (TKI) medication. Patients with CML who are on imatinib, dasatinib, nilotinib, or bosutinib and have had undetectable BCR-ABL by PCR for at least 2 years will stop their tyrosine kinase inhibitor medication.

The study will closely monitor patients for molecular recurrence of their disease after stopping their tyrosine kinase inhibitor medication. Patients will have PCR testing every month for the 1st year, then every other month for the 2nd year, and then every 3 months for the 3rd year. Patients will also answer questions about their symptoms and quality of life before and after stopping their tyrosine kinase inhibitor, on a similar schedule to the PCR testing. Patients who have molecular CML recurrence will restart imatinib, dasatinib, nilotinib, or bosutinib and will continue to be monitored for disease status and patient-reported health status until the end of the study.

Type of study

Treatment discontinuation trials
In a single country

Current status

No longer recruiting patients

Study sponsor

Medical College of Wisconsin with National Institutes of Health (NIH) grant 1R01CA184798-01A1

Scientific lead / contact

Ehab Atallah, eatallah@mcw.edu<mailto:eatallah@mcw.edu>
Kathryn Flynn, kflynn@mcw.edu<mailto:kflynn@mcw.edu>

Principal investigator

Ehab Atallah, Medical College of Wisconsin
Kathryn Flynn, Medical College of Wisconsin

Additional information

Study description in the US register ClinicalTrials.gov, a service of the U. S. National Institutes of Health

Study centers / principal investigators

United States

Florida
Moffitt Cancer Center
Tampa, FL

Georgia
Winship Cancer Institute of Emory University
Atlanta, GA

Illinois
University of Chicago Comprehensive Cancer Center
Chicago, IL

Massachussetts
Dana-Farber Cancer Institute,
Boston, MA

Michigan
Karmanos Cancer Institute of Wayne State University
Detroit, MI

New York
Memorial Sloan Kettering Cancer Center
New York, NY

North Carolina
Duke University Cancer Institute
Durham, NC

Utah
Huntsman Cancer Institute at University of Utah
Salt Lake City, UT

Washington
Fred Hutchinson Cancer Research Center & Seattle Cancer Care Alliance
Seattle, WA

Wisconsin
Froedtert Hospital & Medical College of Wisconsin
Milwaukee, Wisconsin

 

EUREKA = ELN registry

Study title

EUREKA = ELN registry for patients with chronic myeloid leukemia (CML) in chronic phase (CP) who have been treated with tyrosine kinase inhibitors for at least two years

Scientific title

European survey on the assessment of deep molecular response in chronic phase CML patients after at least two years of therapy with tyrosine kinase inhibitors (EUREKA)

Indication and most important inclusion criteria

This European registry enrolls male or female patients from 18 years of age with a diagnosis of BCR-ABL positive CML in chronic phase (CP).
The registry will be available to all CML patients after at least two years of treatment with one or more tyrosine kinase inhibitor(s) (TKIs) at any prescribed dose as per routine clinical practice for a minimum of 24 months at registry entry.

Short description of intervention

The EUREKA registry will collect and evaluate medical data and molecular results of the assessment of residual disease (deep molecular response, MR4.5) in patients with chronic myeloid leukemia (CML) in chronic phase (CP).

Deep molecular response is assessed routinely in the course of treatment of CML. Additional blood sampling will not be required.

Assessment results and biomaterials will be collected, stored and evaluated by specialized laboratories (certified MR4.5 labs). The data analysis is aiming to show the availability of deep molecular response assessment for all CML patients in Europe.

Type of study

Other trial = epidemiological registry

Current status

No longer recruiting

Study sponsor

European LeukemiaNet (ELN)

Scientific lead / contact

...

Principal investigator

Prof. Dr. med. Andreas Hochhaus
Universitätsklinikum Jena
Klinik Innere Medizin II
07740 Jena
Germany

Additional information

Description available at European Treatment and Outcome Study

Study centers / principal investigators

Participating countries:

Austria

Belgium

Bosnia-Herzegovina

Bulgaria

Croatia

Czech Republic

Denmark

France

Germany

Greece

Ireland

Italy

Lithuania

Norway

Poland

Portugal

Rumania

Slovenia

Spain

Switzerland

United Kingdom

 

 

OPTIC = Ponatinib in resistant chronic phase CML [Africa, Asia, Australia, Europe, North- and South America]

Study title

OPTIC = Ponatinib in Patients With Resistant Chronic Phase Chronic Myeloid Leukemia (CML) to Characterize the Efficacy and Safety of a Range of Doses

Scientific title

OPTIC (Optimising Ponatinib Treatment In CML) - A Randomized, Open-label, Phase 2 Trial of Ponatinib in Patients With Resistant Chronic Phase Chronic Myeloid Leukemia to Characterize the Efficacy and Safety of a Range of Doses (EudraCT 2014-001617-12, NCT02467270, AP24534-14-203)

Indication and most important inclusion criteria

This study includes patients who:
- have chronic myeloid leukemia in chronic phase (CP-CML) and are resistant to at least two prior tyrosine kinase inhibitors (TKI)
- are at least 18 years old, have an Eastern Co-Operative Group (ECOG) status of 0-2, have given written informed consent and comply with scheduled visits and study procedures
- have fully recovered from the acute effects of prior cancer therapy before initiation of study drug
- have adequate kidney, liver and pancreas function
- have a negative pregnancy test, use a highly effective form of contraception from randomization through at least 4 months after the end of treatment (for female and male patients who are fertile)

Additional criteria apply.

Short description of intervention

To characterize the efficacy of ponatinib administered in three starting doses (45mg, 30mg, and 15mg daily) in patients with CP-CML who are resistant to at least two TKIs, as measured by major cytogenetic response (MCyR) by 12 months.

Type of study

Therapy optimization trials

Current status

Active, not recruiting

Study sponsor

Ariad Pharmaceuticals (acquired by Takeda)

Scientific lead / contact

Takeda Study Registration Call Center 866-835-2233
globaloncologymedinfo@takeda.com

Principal investigator

See site contact information

Additional information

Study description in the US register ClinicalTrials.gov, a service of the U. S. National Institutes of Health

Study centers / principal investigators

Argentina

Buenos Aires, Argentina, 1221
Hospital Ramos Mejia (Site 826)
Contact: Claudio Merlo
Principal Investigator: Elena B Moiraghi, MD

Caba, Buenos Aires, C1114AAN
Fundaleu (Site 825)
Contact: Miguel Frau
Principal Investigator: Carolina Pavlovsky, M.D.

La Plata, Buenos Aires, B1900AXI
Hospital Italiano La Plata


Australia

New South Wales
St. Leonards, New South Wales, 2065
Royal North Shore Hospital (Site 941)
Contact: Vicki Katsioulas
Principal Investigator: Christopher K Arthur, MD

Adelaide, 5000
Royal Adelaide Hospital, Haematology Clinical Trials (Site 951)
Principal Investigator: Professor Timothy Peter Hughes


Canada

Ontario
Toronto, Ontario, M5G2M9
Princess Margaret Cancer Centre (Site 083)
Principal Investigator: Jeffrey Howard Lipton

Quebec
Montreal, Quebec, H3T IE2
Jewish General Hospital (Site 129)
Contact: Marie Pascale Guay
Principal Investigator: Sarit Assouline, MD

Saskatchewan
Regina, Saskatchewan, S4T 1A5
Pasqua Hospital (Site 227)
Principal Investigator: Haji Chalchal, MD


Chile

Providencia, Santiago, 7500922
Hospital del Salvador (Site 829)
Contact: Maria Gianna Capurro
Principal Investigator: Maria Soledad Undurraga Sutton, MD

Vina del Mar, Valparaiso, 254-0364
Centro de Investigaciones Clínicas Viña del Mar (Site 828)
Contact: Gina Castagneto
Principal Investigator: Christine Rojas Hopkins, MD


Czech Republic
Olomouc, 77520
Fakultni nemocnice Olomoue (Site 515)
Principal Investigator: prof. Karel Indrak, MD, PhD

Praha 2, 128 20
Ustav Hematologie a Krevni Transfuze Praha (UHKT) (Site 516)
Contact: Jana Vedrova
Principal Investigator: Hana Klamova


Denmark

Aarhus C, 8000
Haematologisk Afdeling, Arahus Universitehospital (Site 683)
Principal Investigator: Prof. Jesper Stentoft, M.D.


France

Angers Cedex 9, 44993 CHU Angers
Service Maladies du Sang (Site 685)
Principal Investigator: Dr. Martine Gardembas

Bordeaux, 33076
Centre de Lutte Contre le Cancer - Institut Bergonie (Site 772)
Principal Investigator: Dr. Gabriel Etienne

Lille, Nord, 59037 CEDEX Hopital Claude Huriez CHRU (Site 952)
Contact: Sylvie Brice
Principal Investigator: Valerie Coiteux, MD

Nantes Cedex, 44093
CHU Hotel-Dieu, Service d'Hematologie Clinique (Site 521)
Principal Investigator: Dr. Viviane Dubruille

Nice Cedex 3, 06202
Centre Hospitalier Universitaire de Nice Hopital l'Archet (Site 509)
Contact: Marie-Christine Rigualt
Principal Investigator: Laurence Legros

Poitiers, B.p. 577, 86021
CHRU de Poitiers, Department of Oncology-Hematology and Cell Therapy (Site 954)
Principal Investigator: Prof. Francois Guilhot

Toulouse Cedex 9, Midi-pyrenees, 31059
Institut Universitaire du Cancer de Toulouse Oncopole

Vandoeuvre-les-Nancy Cedex, 54511
University Teaching Hospital - CHU Brabois (Site 953)
Principal Investigator: Dr. Agnes-Paule Guerci-Bresler


Germany

Aachen, 52074
Universitätsklinikum Aachen, AOR (Site 513)
Contact: Sabrina Holst
Principal Investigator: Martina Crysandt, MD

Berlin, 13353
Universitätsmedizin Berlin - Charité (CVK) (Site 701)
Contact: Peggy Grill
Principal Investigator: Philipp Le Coutre, MD

Essen, 45147
Essen University Hospital (Site 686)
Contact: Ilona Vester
Principal Investigator: Jürgen Novotny, MD

Freiburg, 79106
University Hospital Freiburg (Site 527)
Contact: Joana Meisenzahl
Principal Investigator: Nikolas von Bubnoff, MD

Hamburg, 20246
University Cancer Center Hamburg (Site 524)
Hubertus Wald Tumorzentrum
Contact: Juliane Granzow
Principal Investigator: Philippe Schafhausen, MD

Jena, 07740
Universitätsklinikum Jena (Site 946)
Contact: Denise Mathes
Principal Investigator: Andreas Hochhaus, PhD, MD

Mannheim, 68169
University of Heidelberg (Site 947)
Contact: Regina Pleil-Losch
Principal Investigator: Susanne Saussele, MD

Ulm, 89081
University Hospital of Ulm (Site 694)
Contact: Beate Böltau
Principal Investigator: Frank Stegelmann, MD


Italy

Catania, 95124
University Hospital Policlinico (Site 530)
Contact: Giovanna Pappalardo
Principal Investigator: Francesco Di Raimondo, MD

Genova, 16132
V.O. Clinica Ematologica (Site 528)
Contact: Maria Attilia Grassi
Principal Investigator: Marco Gobbi

Monza, 20900
ASST San Gerardo Hospital (Site 355)
Contact: Dario Cerri
Principal Investigator: Carlo Gambacorti-Passerini, MD

Pesaro, Pesaro e Urbino, 61122
A.O. Ospedali Riuniti Marche Nord (Site 689)
Contact: Maurizio Nardelli
Principal Investigator: Giuseppe Visani, MD

Pescara, 65124
Pescara Civil Hospital (Site 688)
Contact: Giuseppina Di Florio
Principal Investigator: Paolo Di Bartolomeo, MD

Roma, 00161
University La Spienza (Site 511)
Contact: Enrica Arduini
Principal Investigator: Giuliana Alimena

Verona, 37134
Ospedale Borgo Roma - Verona (Site 687)
Contact: Giorgia Barbiero
Principal Investigator: Massimiliano Bonifacio, MD


Japan

Fukuoka, 812-0054
Kyushu University Hospital (Site 423)
Contact: Tomoko Nishida
Principal Investigator: Katsuto Takenaka, MD

Kurashiki, Okayama, 710-8602
Kurashiki Central Hospital (Site 427)
Contact: Takako Ikegami
Principal Investigator: Yasunori Ueda, MD

Kyoto, 602-8566
University Hospital Kyoto
Prefectural University of Medicine (Site 419)
Contact: Shigeru Tsukamoto
Principal Investigator: Masafumi Taniwaki

Minatoga, Tokyo, 105-8471
The Jikei University Hospital (Site 428)
Contact: Dai Harada
Principal Investigator: Shingo Yano

Nagoya, Aichi, 464-8681
Aichi Cancer Center Hospital (Site 414)
Contact: Seiji Ohshima
Principal Investigator: Kazuhito Yamamoto

Nishinomiya, Hyogo, 663-8501
Hospital of Hyogo College of Medicine (Site 429)
Contact: Hiroshi Suzuki
Principal Investigator: Masaya Okada, MD

Okayama, 700-8558
Okayama University Hospital (Site 418)
Contact: Toshimitsu Konuma
Principal Investigator: Yoshinobu Maeda, MD

Osaka, 545-0051
Osaka City University Hospital (Site 413)
Contact: Miyuki Amakawa
Principal Investigator: Hirohisa Nakamae

Osaka-Sayama, Osaka, 589-8511
Kindai University Hospital (Site 422)
Contact: Tomoko Kawase
Principal Investigator: Itaru Matsumura

Saga, 849-8501
Saga University Hospital (Site 420)
Contact: Sachiko Takemori
Principal Investigator: Shinya Kimura

Saitama, 350-8550
Saitama Medical Center
Saitama Medical University (Site 416)
Contact: Mashu Morimoto
Principal Investigator: Masahiro Kizaki, MD

Sapporo, Hokkaido, 060-8648
Hokkaido University Hospital (Site 415)
Contact: Norihiro Sakakibara
Principal Investigator: Takanori Teshima

Tokyo, 104-0045
National Cancer Center Hospital (Site 421)
Contact: Yuka Saito
Principal Investigator: Yukio Kobayashi, MD

Tokyo, 108-8639
The Institute of Medical Science
The University of Tokyo (Site 417)
Contact: Minako Kono
Principal Investigator: Arinobu Tojo, MD

Tokyo, 160-0023
Tokyo Medical University Hospital (Site 430)
Contact: Akira Mae
Principal Investigator: Tetsuzo Tauchi


Korea, Republic of

Seoul, Korea, Republic of, 137-701
The Catholic University of Korea Seoul
St. Mary's Hospital (Site 938)
Principal Investigator: Dong-Wook Kim, M.D., PhD


Norway

Bergen, 5021
Bergens Universitetssjukhus (Site 690)
Contact: Ingeborg Tennebekk Nessa
Principal Investigator: Bjorn T Gjertsen, MD, PhD


Poland

Krakow, 30-510
Malopolskie Medical Center (Site 546)
Contact: Marta Kowalowka
Principal Investigator: Tomasz Sacha, MD

Łódź, Poland, 93-510
Klinika Hematologii Uniwersytetu Medycznego w Łodzi (Site 550)
Contact: Magdalena Przybysz
Principal Investigator: Tadeusz Robak, MD

Warszawa, Poland, 02-776
Klinika Hematologii (Site 691)
Contact: Urszula Szustkiewicz
Principal Investigator: Krzysztof Warzocha, MD

Wrocław, Poland, 50-369
Independent Public Clinical Hospital No. 1 in Wroclaw (Site 547)
Contact: Mariusz Grajcar
Principal Investigator: Ewa Medras, MD


Portugal

Lisboa, 1099-023
Instituto Portugues de Oncologia de Lisboa (Site 545)
Contact: Ana Inacio
Principal Investigator: Antonio M Almeida, MD/PhD

Porto, 4200-319
Centro Hospitalar de S. João (Site 559)
Contact: Raquel Ribeiro
Principal Investigator: Manuel S Simões

Russian Federation

Kemerovo, 650066
Kemerovo Regional Clinical Hospital (Site 455)
Contact: Ludmila Chervova
Principal Investigator: Marina Kosinova, MD

Moscow, 111123
Moscow Clinical Scientific Center (Site 453)
Contact: Galina Dudina
Principal Investigator: Mikhail Y Byakhov, MD

Moscow, 125167
Haematological Scientific Center (Site 452)
Contact: Nemchenko Irina, MD
Principal Investigator: Anna Turkina, MD

Saint-Petersburg, 197341
Federal State Budgetary Institution V. A. Almazov
Federal North-West Medical (Site 454)
Contact: Irina Shakhomirova
Principal Investigator: Elza Lomaia, MD


Singapore

Outram Road, Singapore, 169608
Singapore General Hospital (Site 939)
Principal Investigator: Dr. Charles Chuah Thuan Heng


Spain

Barcelona, Cataluna, 08036
Hospital Clinic, Service de Hematologia (Site 963)
Principal Investigator: Francisco Cervantes

Las Palmas de Gran Canaria, Islas Canarias, 35010
Hospital Universitario de Gran Canaria Dr Negrin (Site 692)
Contact: Mireya A Lopez
Principal Investigator: Maria Teresa Gomez Casares, MD

Madrid, 28006
Hospital Universitario de la Princesa
Hematology Service, 2a Planta (Site 555)
Principal Investigator: Juan Luis Steegmann Olmedillas

Madrid, 28034
Hospital Universitario Ramon y Cajal (Site 538)
Principal Investigator: Valentin Garcia Gutierrez
Hospital Clinico Universitario de Valencia (Site 964)

Malaga, Andalucia, 29010
Hospital Regional Universitario Carlos Haya (Site 698)
Principal Investigator: Antonio Jimenez Velasco

Valencia, Spain, 46010
Hospital Clinico Universitario de Valencia (Site 964)
Principal Investigator: Juan Carlos Hernandez Boluda

Valencia, Spain, 46026
Hospital Universitari i Politecnic La Fe (Site 666)
Contact: Maria Tordera
Principal Investigator: Jaime Sanz Caballer


Sweden

Uppsala, SE-751 85
University Hospital Uppsala (Site 945)
Contact: Aime Mukenyuzi
Principal Investigator: Ulla Olsson-Stromberg, M.D., Ph.D.


Switzerland

Zurich, 8091
University Hospital Zurich (Site 562)
Contact: Isabell Pieper-Scholz
Principal Investigator: Stefan Balabanov, MD


Taiwan

Taipei, 100
National Taiwan University Hospital (Site 979)
Principal Investigator: Jih-Luh Tang, M.D., PhD.


United Kingdom

Glasgow, G12 0YN
NHS Greater Glasgow & Clyde
The Beatson West of Scotland Cancer Centre (Site 797)
Principal Investigator: Professor Tessa Holyoake

Liverpool, L7 8XP
The Royal Liverpool University Hospital (Site 969)
Principal Investigator: Professor Richard Clark

London, SE5 9RS
King's College Hospital NHS Foundation Trust (Site 693)
Principal Investigator: Dr. Hugues de Lavallade

London, W120NN
Hammersmith Hospital (Site 967)
Contact: Regina Storch
Principal Investigator: Jane F Apperley, MD

Newcastle Upon Tyne, NE7 7DN
The New Castle Upon Tyne Hospitals NHS Foundation Trust
Freeman Hospital (Site 970)
Contact: Mai Kay Jones
Principal Investigator: Wendy Osborne

Nottingham, NG5 1PB
The Centre for Clinical Haematology
Notthingham University Hospitals NHS Trust (Site 968)
ontact: Maria Scott
Principal Investigator: Jennifer Byrne


United States

Georgia
Atlanta, Georgia, 30322
Emory University Hospital Winship Cancer Institute (Site 058)
Principal Investigator: Vamsi Kota, MD

Indiana
Indianapolis, Indiana, 46237
Indiana Blood and Marrow Transplantation Clinic (Site 138)
Principal Investigator: Luke Akard, MD

Maryland
Baltimore, Maryland, 21201
University of Maryland Medical Center (Site 040)
Principal Investigator: Maria Baer, MD

Michigan
Ann Arbor, Michigan, 48109
University of Michigan Health System (Site 011)
Principal Investigator: Moshe Talpaz, MD

Detroit, Michigan, 48201
Karmanos Cancer Institute (Site 034)
Principal Investigator: Charles Schiffer, MD

Minnesota
Minneapolis, Minnesota, 55455
University of Minnesota Medical School

Nebraska
Omaha, Nebraska, 68198-7680
University of Nebraska Medical Center (Site 235)
Principal Investigator: Lori Maness-Harris, MD

New Jersey
Hackensack, New Jersey, 07601
Hackensack University Medical Center (Site 128)
Principal Investigator: James McCloskey II

New York
New York, New York, 10065
Memorial Sloan Kettering Cancer Center (Site 078)
Contact: Gerald O'Neill
Principal Investigator: Michael Mauro, MD

New York, New York, 10065
Weill Medical College of Cornell University and New York Presbyterian Hospital (Site 006)
Contact: Rachael Alettie
Principal Investigator: Ellen Ritchie, MD

North Carolina
Durham, North Carolina, 27710
Duke University Medical Center (Site 003)
Contact: Cheryl M Maxey
Principal Investigator: Joseph Moore, MD

Ohio
Cleveland, Ohio, 44195
Cleveland Clinic Foundation (Site 004)
Principal Investigator: Dr. Sudipto Mukherjee

Oregon
Portland, Oregon, 97239
Oregon Health & Science University (Site 048)
Contact: Jeanne Liming
Principal Investigator: Michael Heinrich

Pennsylvania
Philadelphia, Pennsylvania, 19104
Abramson Cancer Center (Site 013)
Principal Investigator: Selena Luger, MD

Texas
Houston, Texas, 77030
MD Anderson Cancer Center (Site 005)
Principal Investigator: Jorge E. Cortes, MD

Utah
Salt Lake City, Utah, 84112
Huntsman Cancer Institute (Site 043)
Principal Investigator: Michael Deiningeri, MD

 

 

Subcategories

Please donate!

Please donate!

LogIn

EU e-Privacy Directive